C

Checkpoint Therapeutics
D

CKPT

4.18000
USD
0.02
(0.36%)
مغلق
حجم التداول
33,383
الربح لكل سهم
0
العائد الربحي
-
P/E
-3
حجم السوق
363,743,608
أصول ذات صلة
ABBV
ABBV
0.810
(0.44%)
183.260 USD
AZN
AZN
-0.110
(-0.16%)
70.410 USD
BMY
BMY
-0.140
(-0.30%)
46.870 USD
GILD
GILD
0.670
(0.63%)
107.390 USD
GSK
GSK
-0.560
(-1.43%)
38.690 USD
JNJ
JNJ
0.360
(0.24%)
152.930 USD
LLY
LLY
-7.85
(-1.09%)
713.61 USD
MRK
MRK
-0.220
(-0.28%)
77.600 USD
NVS
NVS
0.240
(0.21%)
112.750 USD
PFE
PFE
0.110
(0.47%)
23.330 USD
المزيد
الأخبار المقالات

العنوان: Checkpoint Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patientswith solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.